Skip to main content

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Surveillance HeartCare® Outcomes Registry

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Surveillance HeartCare® Outcomes Registry

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

ASSIST Registry Studying Various Operator Techniques

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about ASSIST Registry Studying Various Operator Techniques

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Artificially Sweetened Beverage Feeding Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Artificially Sweetened Beverage Feeding Study

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 204
  • Page 205
  • Page 206
  • Page 207
  • Page 208
  • Page 209
  • Page 210
  • Page 211
  • Page 212
  • …
  • Next page Next
  • Last page Last
Subscribe to